Antithrombotic Drugs Market
Number of pages: 100 | Report Format: PDF | Published date: May 29, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 47.65 billion |
|
Revenue Forecast in 2031 |
US$ 90.97 billion |
|
CAGR |
7.45% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Route of Administration, Application, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global antithrombotic drugs market was valued at US$ 47.56 billion in 2022 and is expected to register a revenue CAGR of 7.45% to reach US$ 90.97 billion by 2031.
Antithrombotic Drugs Market Fundamentals
Antithrombotic drugs are a class of medications designed to prevent the formation or growth of blood clots within blood vessels, a process known as thrombosis. These drugs play a crucial role in managing and preventing various cardiovascular and cerebrovascular conditions. Antithrombotic drugs help reduce the risk of thromboembolic events, such as heart attacks, strokes, and deep vein thrombosis, by inhibiting or interfering with the clotting mechanisms in the blood.
These medications are commonly used in patients with a history of cardiovascular disease, those at high risk of developing blood clots, or those undergoing surgical procedures where clotting risks are increased. Effective use of antithrombotic drugs requires careful consideration of the individual patient's condition, risk factors, and potential side effects, as they can have both beneficial and potentially harmful effects on blood clotting.
Researchers believe that antithrombotic drug is an area of active research and development, with several trends and opportunities emerging in this field. There is a growing interest in developing newer anticoagulants that offer improved efficacy, safety, and convenience compared to traditional options. Direct oral anticoagulants (DOACs) have gained popularity in recent years due to their predictable pharmacokinetics and reduced need for monitoring compared to warfarin. Further advancements in this area aim to develop even more selective and targeted anticoagulants with fewer side effects and increased convenience.
Top players in the field of antithrombotic drugs are taking various steps to increase the demand and accessibility of these medications. Pharmaceutical companies invest heavily in research and development to discover and develop new antithrombotic drugs with improved efficacy, safety, and convenience. They focus on identifying novel targets and mechanisms of action to address unmet needs in thrombosis management. This includes exploring new drug classes, such as factor Xa inhibitors and direct thrombin inhibitors, which have shown promise in clinical trials.
Antithrombotic Drugs Market Dynamics
The increase in thrombotic disorders, such as venous thromboembolism, atrial fibrillation, and stroke, has increased demand for antithrombotic drugs. Venous thromboembolism is common. The National Centre for Biotechnology Information states that 600,000 venous thromboembolism events occur annually in the United States. The risk of developing VTE is highest after major surgery, major injury, or during periods of infection and inflammation. This is because blood clots can develop in veins damaged by surgery or injury.
Additionally, the introduction of novel antithrombotic drugs that offer improved efficacy, safety, and convenience is increasingly supporting the global antithrombotic drugs market. For instance, Valeo Pharma recently announced the launch of Redesca, an antithrombotic drug that is a low molecular weight heparin. This drug is effective in treating blood clots and is approved for both prevention and treatment of deep vein thrombosis and pulmonary embolism. Patients found Redesca a versatile option, especially since it comes in a pre-filled syringe, making it easier for them to self-administer. Moreover, Redesca has proven to have a lower risk of bleeding than other antithrombotic drugs, making it a safer option for patients at increased risk of bleeding complications.
Consequently, pharmaceutical companies are increasingly investing in research and development to create next-generation antithrombotic medications, such as direct oral anticoagulants (DOACs) and targeted antiplatelet agents. These drug innovations provide several benefits over traditional options, including reduced bleeding risks, more predictable pharmacokinetics, and simplified dosing regimens. As a result, healthcare providers and patients increasingly adopt these new drugs, leading to market demand and revenue surge.
However, the global antithrombotic drugs market has several restraining factors, such as the risk of bleeding, the cost of treatment, the potential for drug interactions, and the need for regular monitoring. Despite these challenges, antithrombotic drugs remain an important treatment option for preventing and treating thrombotic events.
Antithrombotic Drugs Market Ecosystem
The global antithrombotic drugs market is analyzed from four perspectives: drug class, route of administration, application, and region.
Antithrombotic Drugs Market by Drug Class
Based on drug class, the global antithrombotic drugs market is segmented into thrombolytic drugs, anti-platelet drugs, and anticoagulants.
The anticoagulants segment accounted for the majority of the global antithrombotic drugs market revenue share in 2022. Anticoagulants are a significant component of the antithrombotic drug class and are widely used in preventing and treating thrombotic disorders such as deep vein thrombosis and pulmonary embolism. The rising incidence of these thrombotic disorders is increasingly supporting the growth of the anticoagulants segment. According to the American Lung Association estimate, in January 2023, approximately 900,000 people in the United States will be affected by pulmonary embolism annually. This segment includes both traditional anticoagulants, such as warfarin, and newer oral anticoagulants, known as direct oral anticoagulants (DOACs), which have gained significant market acceptance in recent years.
Antithrombotic Drugs Market by Route of Administration
Based on the route of administration, the global antithrombotic drugs market is segmented into parenteral and oral.
The oral segment accounted for the majority of revenue share in the global antithrombotic drugs market. Patients find oral administration of medications to be convenient and easy to use, as it eliminates the need for injections or invasive procedures. Due to its simplicity and non-invasiveness, many patients prefer oral medications, resulting in higher adherence and compliance rates. The oral route of administration is especially favorable for patients with long-term and chronic conditions who require ongoing antithrombotic therapy.
The parenteral segment is expected to show high revenue CAGR in the forecast years. Parenteral antithrombotic drugs play a vital role in managing thrombotic emergencies, such as acute ischemic stroke, massive pulmonary embolism, and unstable angina. Increasing incidences of thrombotic emergencies are the key factor supporting segmental growth. In 2023, the Centers for Diseases Control and Prevention stated that around 87% of all strokes are ischemic strokes in the United States. These conditions often necessitate immediate and potent anticoagulation, which can be achieved more effectively through parenteral routes.
Antithrombotic Drugs Market by Application
Based on application, the global antithrombotic drugs market is segmented into atrial fibrillation, deep vein thrombosis, and pulmonary embolism.
The atrial fibrillation segment accounted for a significant revenue share in the global antithrombotic drugs market. Antithrombotic drugs are frequently prescribed to patients with atrial fibrillation. Atrial fibrillation increases the risk of blood clot formation in the heart chambers, which can then travel to other parts of the body and cause strokes or systemic embolism. According to the Centers for Disease Control and Prevention, more than 454,000 hospitalizations with atrial fibrillation as the primary diagnosis happen yearly in the United States. The condition contributes to about 158,000 deaths each year.
Antithrombotic Drugs Market by Region
Based on the region, the antithrombotic drugs market is segmented into North America, Europe, Asia Pacific, Latin America, & the Middle East & Africa.
North America accounted for the majority of antithrombotic drugs market revenue share in 2022. This can be attributed to the region's high prevalence of cardiovascular diseases and the increasing adoption of antithrombotic drugs for their treatment. In 2022, according to the National Center for Biotechnology Information, approximately 600,000 cases of venous thromboembolism are reported each year in the United States. The United States is the largest market for antithrombotic drugs in North America, followed by Canada and Mexico.
The Asia Pacific antithrombotic drugs market is projected to show a significant growth of 8.2% CAGR in the forecast years. The Asia Pacific region is experiencing a rising prevalence of cardiovascular diseases, including atrial fibrillation, deep vein thrombosis, and pulmonary embolism. The Journal of Arrhythmia reported in 2021 that the prevalence of atrial fibrillation in Asia-Pacific countries ranges from 0.49% to 5.4%. Moreover, the region is also witnessing an increase in the aging population, which is further driving the demand for antithrombotic drugs. The elderly population is more susceptible to cardiovascular diseases and requires prolonged medication, which is expected to boost the growth of the antithrombotic drugs market in the Asia Pacific region.
Antithrombotic Drugs Market Competitive Landscape
Several companies emphasize development tactics, such as new launches, product approvals, and other elements like patents and events. The market saw acquisition, partnership, and cooperation activities as inorganic development tactics. These initiatives have enabled the expansion of future economic business prospects and increased demand for calcitonin in the global antithrombotic drugs market.
Some of the prominent companies having the largest revenue share in the global antithrombotic drugs market are,
Antithrombotic Drugs Market Strategic Developments
Antithrombotic drugs are a class of medications designed to prevent the formation or growth of blood clots within blood vessels, a process known as thrombosis.
The global antithrombotic drugs market was valued at US$ 90.97 billion by 2031.
The global antithrombotic drugs market has witnessed significant growth in recent years due to the increasing incidences of coagulation disorders and increasing innovations in drugs.
The global antithrombotic drugs market is expected to register a revenue CAGR of 7.45% in the forecast period from 2023 to 2031.
North America region has dominated the global antithrombotic drugs market in 2022.
*Insights on financial performance are subject to the availability of information in the public domain